ArticleNeurotoxicity research2012
Integrin β8 signaling in neonatal hypoxic-ischemic brain injury.
Article in Neurotoxicity research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 9 citations in OpenAlex.
- Whole exome sequencing identified genetic variations in Chinese hemangioblastoma patients.American journal of medical genetics. Part A · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Integrin β8 is a key regulator of vascular homeostasis in brain development and in vitro studies show that β8 protects against oxygen-glucose deprivation-induced neuronal apoptosis. However, the role β8 plays in vivo in neonatal rats with hypoxic-ischemic (HI) brain injury is not known. Here, we report the function of β8 and signaling pathways involved in neuroprotection after neonatal brain HI. Neonatal HI model was performed in postnatal day 10 rats by ligating the right common carotid artery, followed by hypoxia exposure. Expressions of β8 were determined by immunohistochemistry, immunofluorescence, reverse transcription polymerase chain reaction, and western blot. We used lentiviral vector-mediated β8 RNAi to inhibit integrin β8, GM6001 to inhibit matrix metalloprotease, and the TGF-β1 neutralizing antibody 1d11 to inhibit TGF-β1. The expression of vascular endothelial growth factor, ERK1/2 and p-ERK1/2, Bcl-2, Bax, and cleaved caspase 3 (CC3) were detected by western blot. Cellular apoptosis was detected with terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick end labeling. β8 was mainly localized to astrocytes and upregulated immediately upon HI. When β8/TGF-β1 was inhibited, phosphorylated ERK1/2 was downregulated, followed by the downregulation of vascular endothelial growth factor (VEGF) and Bcl-2/Bax, and upregulation of CC3 and cellular apoptosis. The activation of TGF-β1 and ERK1/2 are involved in β8-induced VEGF expression and neuronal survival. The anti-apoptotic effect of β8 may be attributed to regulation of Bcl-2/Bax balance and caspase 3. β8 might be a potential target for therapeutic intervention in neonates with HI brain injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.